Cyclerion CY6463 shows cognition effect size 0.60 in CIAS study; well tolerated

Cyclerion Therapeutics, Inc.

Effect size 0.60 on Cogstate Schizophrenia Battery composite after 14 days of 15 mg CY6463 vs placebo.
No SAEs, severe AEs, or discontinuations due to AEs; all adverse events transient.
Favorable changes observed in broad panel of plasma inflammatory biomarkers linked to schizophrenia.
48 adults with stable schizophrenia on single atypical antipsychotic; PK linear dose-proportional.
Company exploring partnerships; webinar July 28 at 8:00 a.m. EDT to discuss data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.